# Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

> **NCT00610363** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 83 (actual)

## Conditions studied

- Gout

## Interventions

- **BIOLOGICAL:** Rilonacept
- **OTHER:** Placebo (for Rilonacept)

## Key facts

- **NCT ID:** NCT00610363
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2017-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00610363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00610363, "Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00610363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*